A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients

INTRODUCTION: Selexipag, an oral nonprostanoid prostaglandin receptor agonist, has led to reduced morbidity and mortality in adults with pulmonary arterial hypertension (PAH). While the adult literature has been extrapolated to suggest selexipag as an oral treatment for severe pediatric pulmonary hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Youssef, David, Richards, Susan, Lague, Sabine, Sheppard, Catherine, Smith, Jenna, Vorhies, Erika, Hosking, Martin, Pietrosanu, Matthew, Bates, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011093/
https://www.ncbi.nlm.nih.gov/pubmed/36925667
http://dx.doi.org/10.3389/fped.2023.1055158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011093/
https://www.ncbi.nlm.nih.gov/pubmed/36925667
http://dx.doi.org/10.3389/fped.2023.1055158

Ejemplares similares